Jared Gollob, M.D., is a distinguished medical professional currently serving as the Chief Medical Officer at Kymera Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies for serious diseases. Dr. Gollob brings a wealth of experience in clinical development, medical affairs, and oncology to his role. He earned his medical degree from the University of Pennsylvania School of Medicine and completed his residency in internal medicine at the Hospital of the University of Pennsylvania. He further honed his expertise through a fellowship in medical oncology at the Dana-Farber Cancer Institute, affiliated with Harvard Medical School. Throughout his career, Dr. Gollob has held several key leadership positions in the biopharmaceutical industry. Prior to joining Kymera Therapeutics, he served as the Chief Medical Officer at Aileron Therapeutics, where he played a pivotal role in advancing the company's clinical programs. His earlier career also includes significant contributions at EMD Serono, where he led the development of oncology therapies, and at Synta Pharmaceuticals, where he was instrumental in the clinical development of novel cancer treatments. Dr. Gollob's work has been widely recognized, and he has authored numerous publications in peer-reviewed journals, contributing valuable insights to the field of oncology. As Chief Medical Officer at Kymera Therapeutics, Dr. Gollob is responsible for overseeing the clinical development strategy and execution of the company's pipeline of targeted protein degradation therapies. His leadership is crucial in navigating the complex landscape of drug development and bringing innovative treatments to patients with unmet medical needs. Dr. Gollob's extensive experience and strategic vision are key assets in driving Kymera Therapeutics forward in its mission to transform the treatment of serious diseases.